Literature DB >> 32651768

Role of nebulized epinephrine in moderate bronchiolitis: a quasi-randomized trial.

Faiza Yasin1, Zahir Shah Afridi2, Qasim Mahmood2, Akhter Ali Khan2, Sharon Condon2, Rizwan Ahmed Khan2.   

Abstract

BACKGROUND/AIMS: Bronchiolitis is the most common lower respiratory illness that characteristically affects the children below 2 years of age accounting about 2-3% of patients admitted to hospital each year [1-4]. We compared the effect of racemic epinephrine (RE) and 3% hypertonic saline (HS) nebulization on the length of stay (LOS) in the hospital.
METHODS: We looked at the infants with moderate bronchiolitis, from October 2013 to March 2014. Out of eighty cases, 16 in HS and 18 in RE groups were enrolled. At the time of admission, 0.2 ml of RE added to 1.8 ml of distilled water was nebulized to RE group, as compared with 2 ml of 3% HS in nebulized form. RE was re-administered if needed on 6 h in comparison with 3% HS at the frequency of 1 to 4 h.
RESULTS: One infant from RE group and three infants from HS group were excluded due to progression towards severe bronchiolitis. The LOS in RE group ranged between 18 and 160 h (mean 45 h), while in HS group, LOS was 18.50-206 h (mean 74.3 h). The LOS was significantly short in RE group (p value 0.015) which was statistically significant.
CONCLUSION: Racemic epinephrine nebulization as first-line medication may significantly reduce the length of hospital stay in infants with moderate bronchiolitis in comparison with nebulized HS.

Entities:  

Keywords:  Bronchiolitis; Epinephrine; Hypertonic saline; Length of Hospital stay

Mesh:

Substances:

Year:  2020        PMID: 32651768     DOI: 10.1007/s11845-020-02293-5

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  1 in total

1.  Hypertonic saline/epinephrine treatment in hospitalized infants with viral bronchiolitis reduces hospitalization stay: 2 years experience.

Authors:  Guy Tal; Karine Cesar; Anat Oron; Sion Houri; Ami Ballin; Avigdor Mandelberg
Journal:  Isr Med Assoc J       Date:  2006-03       Impact factor: 0.892

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.